Get started

Stocksanalysis

UNLOCK PROFITS! 5 Opportunities to Capitalise1. Tesla (Weekly Timeframe) NASDAQ:TSLA ● A symmetrical triangle pattern is clearly visible on the weekly chart. ● Following a recent breakout with strong volume, the price is likely to rise significantly. 2. Lam Research Corporation (Weekly Timeframe) NASDAQ:LRCX ● After breaking out of the cup and handle pattern, the price surged to an all-time high around the 113 level. ● A notable rejection from this peak caused a pullback to the previous breakout level. ● The price is currently consolidating at this level, preparing for a potential upward move. 3. Tapestry (Daily Timeframe) NYSE:TPR ● The stock has been trading within a rectangle pattern for a while. ● Now, following a robust breakout supported by significant volume, the stock price is primed for an upward trajectory. 4. Oppenheimer Holdings (Daily Timeframe) NYSE:OPY ● After breaking out of a bullish pennant pattern, the stock price is targeting higher levels. ● The breakout was accompanied by significantly high trading volume. 5. Deckers Outdoor Corporation (Daily Timeframe) NYSE:DECK ● The stock price has formed a symmetrical triangle pattern. ● A recent breakout could drive the price to higher levels.
NASDAQ:TSLALong
by NaranjCapital
Abbott Labs Shakes Off Downtrend, Sets Sights on $142 milestoneIn December 2021, the stock price hit an all-time high near the 142 mark, after which it experienced a significant drop. Following this decline, the price found support around the 90 level and began to recover. Last week, the stock managed to break through the upper boundary of the descending parallel channel, setting the stage for additional upward momentum. An immediate resistance level is noted at the 122 level, and a substantial movement is expected if this level is surpassed.
NYSE:ABTLong
by NaranjCapital
The Payment Card Titan: Comparing Visa, Mastercard, and Amex◉ Abstract The global credit card market is projected to grow from USD 559.18 billion in 2023 to USD 1,146.62 billion by 2033, driven by advancements in digital payment technologies, e-commerce growth, increased financial literacy, and urbanization, especially in Asia-Pacific. Visa leads the market with a 38.73% share, followed by Mastercard and American Express. Visa and Mastercard operate primarily as payment networks, while American Express both issues cards and offers unique rewards. Financially, all three companies show strong revenue growth, with American Express yielding the highest ROI but also carrying significant debt. Despite this debt, American Express appears undervalued based on financial ratios. Overall, while American Express presents an attractive investment opportunity, Visa and Mastercard also demonstrate solid fundamentals and growth potential for investors in the expanding credit card market. Read the full analysis here . . . ◉ Introduction The Global Credit Card Market Size was Valued at USD 559.18 Billion in 2023 and the Worldwide Credit Card Market Size is Expected to Reach USD 1146.62 Billion by 2033, ◉ Key Growth Drivers ● Digitalization and Technology: Advancements in payment technologies, including mobile wallets and contactless payments, enhance convenience and security. ● E-Commerce Growth: The rise of online shopping increases demand for credit card payments, as consumers prefer their ease and safety. ● Financial Literacy: Improved understanding of financial products encourages more consumers, especially in developing regions, to adopt credit cards. ● Urbanization: Growing urban populations, particularly in Asia-Pacific, lead to greater access to banking services and credit facilities. ● Emerging Markets: Rising disposable incomes in developing countries drive new credit card accounts as financial institutions expand their offerings. ● Consumer Convenience: The preference for quick and easy payment methods boosts credit card usage over cash transactions. ● Rewards Programs: Attractive loyalty programs incentivize consumers to use credit cards for everyday purchases. ● Regulatory Support: Government initiatives promoting cashless transactions foster a favourable environment for credit card adoption. ◉ Market Overview As of 2022, the global credit card market was primarily led by Visa, which held a 38.73% share of the worldwide payment volume. Mastercard followed with a 24% market share, while American Express (Amex) accounted for 4.61%. Notably, China UnionPay is also a major player in this space, surpassing Amex in terms of purchase volume ◉ Key Players in the Payment Card Industry 1. Visa NYSE:V ● Market Cap: $552 B ● Market Share: 38.73% ● Business Model: Payment network facilitating transactions between consumers, businesses, banks, and governments globally. ● Card Issuance: Does not issue cards itself. ● Global Reach: Extensive acceptance network across more than 200 countries. 2. Mastercard NYSE:MA ● Market Cap: $474 B ● Market Share: 24% ● Business Model: Payment processor and network partnering with banks to offer various card products. ● Card Issuance: Does not issue cards itself. ● Global Reach: Broad acceptance worldwide with diverse products catering to different consumer needs. 3. American Express NYSE:AXP ● Market Cap: $203 B ● Market Share: 4.61% ● Business Model: Card issuer and payment network offering unique benefits and rewards directly to cardholders. ● Card Issuance: Issues its own cards. ● Global Reach: High acceptance rate in the US (99% of merchants), lower in Europe and Asia due to higher transaction fees. ◉ Technical Aspects ● From a technical perspective, there's a notable similarity among the three stocks: each is exhibiting strong bullish momentum, consistently achieving higher highs and higher lows. ● All three stocks have formed a Rounding Bottom pattern, and after breaking out, their prices have climbed to new heights. ● While Mastercard and American Express are currently trading at their all-time highs, Visa is positioned just below its peak. ◉ Relative Strength The chart vividly demonstrates that American Express has excelled remarkably, achieving a return of nearly 85%, whereas Mastercard and Visa have delivered returns of 28% and 20%, respectively. ◉ Revenue & Profit Analysis 1. Visa ● Year-over-Year ➖ In FY23, Visa achieved a remarkable revenue increase of 11.4%, reaching $32.7 billion, up from $29.3 billion in FY22. ➖ The EBITDA for FY23 also saw a significant rise, totalling $22.9 billion compared to $20.6 billion in FY22. ● Quarter-over-Quarter ➖ In the latest June quarter, Visa's revenue rose to $8.9 billion, slightly surpassing the $8.8 billion reported in March 2024. This reflects a year-over-year growth of nearly 9.5% from $8.1 billion in the same quarter last year. ➖ The EBITDA for the most recent June quarter reached $6.2 billion, indicating an almost 9% increase from $5.7 billion in the same quarter last year. ➖ In June, the diluted EPS saw a modest rise, climbing to $9.35 (LTM) from $8.94 (LTM) in March 2024, which represents a notable year-over-year increase of 18.6% from $30.3 (LTM). 2. Mastercard ● Year-over-Year ➖ Mastercard's revenue for FY23 experienced a robust growth of 12.9%, reaching $25.1 billion, up from $22.2 billion in FY22. ➖ The EBITDA for FY23 also increased, reporting $22.9 billion, up from $20.6 billion in FY22. ● Quarter-over-Quarter ➖ In the recent June quarter, Mastercard's revenue climbed to $7.0 billion, compared to $6.3 billion in March 2024. Year-over-year, this marks an increase of nearly 11% from $6.3 billion in the same quarter last year. ➖ The EBITDA for the latest June quarter was $4.4 billion, reflecting an almost 9% rise from $3.9 billion in March 2024. ➖ In June, the diluted EPS saw a slight increase, rising to $13.08 (LTM) from $12.59 (LTM) in March 2024, which is a significant year-over-year increase of 23% from $10.67 (LTM). 3. American Express ● Year-over-Year ➖ For the fiscal year 2023, the company experienced a remarkable revenue growth of 9.7%, reaching an impressive $55.6 billion, compared to $50.7 billion in fiscal year 2022. ➖ Additionally, operating income showed a positive trajectory, with fiscal year 2023 reporting $10.8 billion, an increase from $10 billion in the previous fiscal year. ● Quarter-over-Quarter ➖ In the latest June quarter, revenue continued its upward trend, totalling $15.1 billion, up from $14.5 billion in March 2024. This represents a significant year-over-year growth of nearly 8.7% from $13.9 billion in the June quarter of the previous year. ➖ Furthermore, operating income for the June quarter reached $3.2 billion, marking a substantial increase of almost 19% from $2.7 billion in the same quarter last year. ➖ The diluted earnings per share (EPS) also saw a remarkable rise in June, climbing to $13.39 (LTM) from $12.14 (LTM) in March 2024, which is a significant jump of 36% compared to $9.83 (LTM) in the same quarter last year. ◉ Valuation ● P/E Ratio ➖ Visa stands at a P/E ratio of 29.1x. ➖ Mastercard is at a P/E ratio of 38.7x. ➖ American Express shows a P/E ratio of 20.6x. ➖ When we analyze these figures, it becomes clear that American Express appears significantly undervalued compared to its peers. ● P/B Ratio ➖ Visa has a P/B ratio of 14.3x. ➖ Mastercard's P/B ratio is a staggering 64x. ➖ American Express, however, has a P/B ratio of just 6.8x. This further reinforces the notion that American Express is currently undervalued in the market. ● PEG Ratio ➖ Visa's PEG ratio is 1.56. ➖ Mastercard's PEG stands at 1.71. ➖ American Express shines with a PEG ratio of just 0.56. ➖ This metric also highlights American Express's superior value proposition compared to its peers. ◉ Cash Flow Analysis ➖ Visa's operating cash flow for the fiscal year 2023 has risen to $20.8 billion, marking a notable increase from $18.8 billion in fiscal year 2022. ➖ Similarly, Mastercard has experienced growth in its operating cash flow, which has reached $12 billion in fiscal year 2023, up from $11.2 billion in the previous year. ➖ In contrast, American Express has reported a significant decline in its operating cash flow, decreasing from $21.1 billion in fiscal year 2022 to $18.6 billion in fiscal year 2023. ◉ Debt Analysis 1. Visa ● Debt to Equity Ratio: Approximately 0.52 as of June 2024, indicating a stable financial structure with moderate leverage. ● Total Debt: About $20.6 billion. ● Total Shareholder Equity: $39.7 billion. ● Analysis: Visa's ratio reflects a cautious debt approach, balancing equity and debt financing, with net debt well-supported by operating cash flow, enhancing financial stability. 2. Mastercard ● Debt to Equity Ratio: Approximately 2.10, indicating a higher reliance on debt compared to Visa 5. ● Total Debt: $15.6 billion. ● Total Shareholder Equity: $7.5 billion. ● Analysis: Mastercard’s higher ratio suggests it is more aggressive in leveraging debt for growth initiatives compared to Visa. This strategy may lead to greater volatility in earnings due to interest obligations. 3. American Express ● Debt to Equity Ratio: Approximately 1.80, indicating a significant level of debt relative to equity 5. ● Total Debt: $53.2 billion. ● Total Shareholder Equity: $29.54 billion. ● Analysis: American Express’s ratio shows a strong reliance on debt financing, which can enhance growth but also introduces risks related to interest payments and market conditions. ◉ Top Shareholders 1. Visa ● The Vanguard Group has notably boosted its investment in Visa, now commanding a remarkable 7.52% share, reflecting a 0.62% increase since the close of the March quarter. ● In contrast, Blackrock maintains a stake of approximately 6.7% in the firm. 2. Mastercard ● When it comes to Mastercard, Vanguard has also made strides, raising its ownership to an impressive 8.27%, which is a 1.02% uptick since the end of March. ● Blackrock, on the other hand, has a substantial 7.56% stake, showing a 1.17% growth from the same period. 3. American Express ● As for American Express, Warren Buffet’s Berkshire Hathaway boasts a significant 21.3% stake in the company. ● Meanwhile, Vanguard holds a 6.36% interest, while Blackrock has a 5.89% share. ◉ Conclusion After a thorough analysis of both technical and financial indicators, we find that American Express offers a compelling valuation opportunity that is likely to attract investors. Nonetheless, it is important to recognize the significant debt load the company carries, a concern that also extends to Mastercard. ● From a technical standpoint, the chart for American Express seems to be stretched thin. Investors might want to hold off for a corrective dip to secure a more advantageous entry point. ● Mastercard's financial results reflect solid performance, though it carries a high level of debt. The technical chart indicates a slight overvaluation. Savvy investors might look to build their positions during times of price stabilization. ● Visa presents a well-rounded synergy between its technical and fundamental metrics. Its chart reveals a remarkable rebound, approaching previous all-time highs after a notable decline. The company's valuation and growth potential make it a compelling investment choice.
Editors' picks
NYSE:VLong
by NaranjCapital
7
Globus Medical: Approaching resistance, is a breakthrough comingWeekly Chart ● The stock has tested the trendline resistance multiple times. ● Currently, it is trading just below this level. ● A breakout above this resistance is anticipated in the near future. ● Following the breakout, the price may increase. Daily Chart ● A Symmetrical Triangle pattern has formed. ● A strong breakout has taken place, supported by significant volume. ● The price is now set for a potential upward movement.
NYSE:GMEDLong
by NaranjCapital
Exxon's Make-or-Break Moment: $123 Resistance in FocusThe chart distinctly illustrates that the stock has been in a consolidation phase for over a year and is presently trading slightly below its resistance zone. For a potential upward movement, the price must surpass the 123 level and maintain its position above this threshold. At the same time, there is a significant likelihood that the stock price may encounter rejection once more, leading to a decline towards its trendline support level.
NYSE:XOM
by NaranjCapital
1
Ralph Lauren: Elevate Your Wealth with the Essence of Luxury◉ Abstract Ralph Lauren is thriving in the booming luxury apparel market. The company, founded in 1967, has a market cap of $11.83 billion and generates nearly 44% of its revenue from North America, totaling $2.93 billion. The industry is valued at approximately $110.13 billion in 2024 and projected to reach $151.32 billion by 2029, growing at a CAGR of 6.56%. Recent technical analysis shows Ralph Lauren's stock has outperformed the NYSE Composite index with a 66% annual return. Despite a slight revenue increase of 2.9% year-on-year, EBITDA soared to $1,024 million, reflecting strong financial health. With a current P/E ratio of 17.4x, Ralph Lauren presents an attractive investment opportunity amidst rising global wealth and consumer demand for luxury goods. Read full analysis here . . . ◉ Introduction The global luxury apparel market is currently experiencing significant growth, driven by various factors including increasing disposable incomes, brand loyalty, and the rising influence of social media on consumer behaviour. Here’s a detailed overview of the market size and growth outlook: ◉ Current Market Size According to Mordor Intelligence, the global luxury apparel market was valued at approximately USD 110.13 billion in 2024, with expectations to grow to USD 151.32 billion by 2029, reflecting a CAGR of 6.56%. ◉ Growth Drivers ● Increasing Wealth: The rising number of millionaires globally and growing middle-class affluence, particularly in regions like Asia-Pacific, are significant contributors to luxury apparel demand. ● Consumer Trends: There is a growing perception that luxury goods enhance social status, which fuels consumer interest in high-end fashion. ● Digital Influence: Enhanced online shopping experiences and the effective use of social media for marketing have opened new avenues for luxury brands to reach consumers. ◉ Regional Insights ● Europe Dominant Market: Holds a market share of approximately 34% to 43%. The presence of numerous luxury brands and high purchasing power among consumers drive demand, supported by significant tourist spending on luxury goods. ● North America Strong Demand: The U.S. is a key player, characterized by a wealthy consumer base and increasing brand loyalty, particularly among younger generations who view luxury items as status symbols. ● Asia-Pacific Fastest Growing Market: Anticipated to grow rapidly due to rising disposable incomes and brand awareness, especially in countries like China and India. ● Latin America Emerging Potential: Currently holds a smaller market share but shows promise for growth as consumer awareness and travel increase. ● Middle East & Africa Limited Contribution: This region contributes the least to the luxury apparel market, although countries like the UAE are seeing growth due to tourism. The overall outlook for the luxury apparel market remains optimistic, supported by evolving consumer preferences and increasing global wealth. Amidst the global luxury apparel market's promising growth prospects, we have identified Ralph Lauren as a prime opportunity for investment. With its robust financial performance and impressive technical indicators, Ralph Lauren is well-positioned to propel success. ◉ Company Overview Ralph Lauren Corporation NYSE:RL is a renowned American fashion company known for its high-quality, luxury lifestyle products. Founded in 1967 by the iconic designer Ralph Lauren, the company has become a global symbol of timeless style and sophistication. The company offers a wide range of products, including apparel, footwear, accessories, home goods, fragrances, and hospitality. Ralph Lauren's iconic polo shirt and strong brand identity have contributed to its success, making it a global leader in the luxury fashion industry. ◉ Investment Advice 💡 Buy Ralph Lauren Corporation NYSE:RL ● Buy Range - 190 - 193 ● Sell Target - 245 - 250 ● Potential Return - 27% - 30% ● Approx Holding Period - 8-10 months ◉ Market Capitalization - $11.83 B ◉ Peer Companies ● Tapestry NYSE:TPR - $10.59 B ● Levi Strauss NYSE:LEVI - $8.57 B ● PVH Corp. NYSE:PVH - $5.44 B ● Columbia Sportswear Company NASDAQ:COLM - $4.87 B ◉ Relative Strength The chart clearly illustrates that Ralph Lauren has greatly outperformed the NYSE Composite index, achieving an impressive annual return of 66%. ◉ Technical Aspects ● Monthly Chart ➖ The monthly chart clearly shows that the stock price faced several rejections near the 190 level, which ultimately triggered a significant drop, brought the price down to the 66 level. ➖ Afterward, the price experienced various fluctuations and, after a prolonged consolidation phase, developed an Inverted Head & Shoulders pattern. ➖ Upon breaking out, the price surged upward but encountered resistance again at the previous resistance zone. ➖ However, after a pullback, the stock has successfully surpassed this resistance for the first time in almost 11 years. ● Daily Chart ➖ On the daily chart, the price has formed a Rectangle pattern following a brief consolidation phase and has recently made a breakout. ➖ If the price can hold above the 190 level, we can expect a bullish movement in the coming days. ◉ Revenue Breakdown - Location Wise Ralph Lauren Corporation is a global luxury brand with a strong presence in various regions. ➖ North America remains Ralph Lauren's biggest market, contributing nearly 44% of its total revenue, which amounts to $2.93 billion. ➖ In Europe , the brand is seeing consistent growth, with revenue reaching around $2 billion, making up about 30% of total earnings. ➖ Asia , especially China, is becoming a key player for Ralph Lauren, generating approximately $1.58 billion, or 24% of total revenue. ◉ Revenue & Profit Analysis ● Year-on-year ➖ In the fiscal year 2024, the company achieved a modest revenue increase of 2.9%, totaling $6,631 million, compared to $6,443 million in the prior year. ➖ On the other hand, EBITDA growth has been remarkable, soaring to $1,024 million from $801 million in FY23. The current EBITDA margin stands at an impressive 15.5%. ➖ Additionally, diluted earnings per share (EPS) experienced a substantial year-over-year rise of 28%, reaching $9.71 in FY24, up from $7.58 in FY22. ● Quarter-on-quarter ➖ In terms of quarterly performance, the company reported a decline in sales over the last three quarters, with the most recent quarter showing sales of $1,512 million, down from $1,568 million in March 2024 and $1,934 million in December 2023. ➖ Nevertheless, EBITDA demonstrated significant growth in the June quarter, climbing to $265 million from $176 million in March 2023. ◉ Valuation ● P/E Ratio ➖ Current P/E Ratio vs. Median P/E Ratio The current price-to-earnings ratio for this stock stands at 17.4x, which is notably elevated compared to its four-year median P/E ratio of 5.7x. This suggests that the stock is presently overvalued. ➖ Current P/E vs. Peer Average P/E When evaluating the stock's Price-To-Earnings Ratio of 17.4x, it shows a more attractive valuation, as it is lower than the peer average of 25.5x. ➖ Current P/E vs. Industry Average P/E RL is positioned at a more appealing price point, with a Price-To-Earnings Ratio of 17.4x, which is significantly less than the US Luxury industry's average of 19.x. ● P/B Ratio ➖ Current P/B vs. Peer Average P/B The current P/B ratio reveals that the stock is considerably higher than its peers, with a ratio of 5x compared to the peer average of 3x. ➖ Current P/B vs. Industry Average P/B In comparison to the industry average, RL's current P/B ratio of 5x indicates that it is substantially overvalued, as the industry average is only 2.2x. ● PEG Ratio A PEG ratio of 0.54 suggests that the stock is undervalued relative to its expected earnings growth. ◉ Cash Flow Analysis In fiscal year 2024, operational cash flow experienced remarkable growth, reaching $1,069 million, a substantial increase from $411 million in fiscal year 2023. ◉ Debt Analysis The company currently holds a long term debt of $1,141 million with a total equity of $2,367 million, makes long-term debt to equity of 48%. ◉ Top Shareholders ➖ The Vanguard Group has significantly increased its investment in this stock, now owning an impressive 8.23% stake, which marks a 3.9% rise since the end of the March quarter. ➖ Meanwhile, Blackrock holds a stake of around 4.11% in the company. ◉ Conclusion After a thorough evaluation, we find that Ralph Lauren Corporation is strategically poised to thrive in the expanding luxury apparel market, driven by increasing disposable incomes and a growing appetite for high-end products.
NYSE:RLLong
by NaranjCapital
Coca-Cola's Bull Run Intensifies: Pole & Flag Breakout Expected!The chart shows that the stock price encountered resistance near the $65 level, subsequently dropping to $52, where it found support. After rebounding from this support, the price began to rise, successfully breaking through the Inverted Head & Shoulders pattern that had formed during the consolidation phase. Following this breakout, the price entered another consolidation period, created an Ascending Triangle Pattern. With another breakout, the stock price surged to an all-time high of $73.5 before experiencing a pullback. A bullish Pole & Flag pattern has emerged on the chart, signaling a potential continuation of the upward trend. It is expected that the price will break through this pattern and reach new highs in the near future.
NYSE:KOLong
by NaranjCapital
2
Corcept Therapeutics: A Shining Star in US BiotechCorcept Therapeutics is making waves in the booming U.S. biotech scene, with its stock surging 46.2% over the past six months. The company, known for its Cushing's syndrome drug, Korlym, reported a staggering 39.1% year-over-year sales increase, reaching $310.6 million in H1 2024. With a market cap of $4.42 billion, Corcept is actively developing new treatments like Relacorilant, which shows promise in clinical trials. Despite a high PE ratio of 35.3x compared to the industry average of 19x, its strong revenue growth and commitment to R&D position it as a solid investment opportunity in the fast-growing biotech market projected to reach $1,786 billion by 2033. ◉ The US Biotech Industry Outlook The biotech boom in the U.S. is hotter than a California summer! Fueled by groundbreaking tech and government cheerleading, the industry is soaring higher than a SpaceX rocket. According to Vision Research Reports, the market is projected to soar by 12.4% CAGR from 2024 to 2033. This rapid expansion is driven by advancements in areas like genomics, gene editing, and personalized medicine, positioning the U.S. as a global leader in healthcare innovation. ➖ The US biotechnology market size was valued at $552.43 billion in 2023 and is anticipated to hit around $1,786 billion by 2033. ➖ Key players like Abbvie Inc., Genentech Inc., and Amgen Inc. are leading the market. Acknowledging the remarkable expansion of the biotech sector, we are taking a closer look at a stock that is showing considerable strength in its technical chart, complemented by robust financial performance. ◉ Company Overview Corcept Therapeutics NASDAQ:CORT is a biopharmaceutical company dedicated to developing innovative treatments for severe endocrine, oncologic, and metabolic disorders. Their lead product, Korlym, is approved for Cushing's syndrome, a rare endocrine condition. Corcept is also advancing several pipeline candidates, including relacorilant for Cushing's syndrome, treatments for various cancers, and potential therapies for neurological conditions like amyotrophic lateral sclerosis and nonalcoholic steatohepatitis. Founded in 1998, Corcept is based in Menlo Park, California. ◉ Significant Stock Performance of Corcept Therapeutics Corcept Therapeutics Incorporated's stock price has risen 46.2% in the past six months, despite a 2% industry decline. This surge is attributed to strong demand for Korlym, the company's sole marketed drug used to treat Cushing's syndrome, a condition that is primarily cured with mifepristone. ◉ The Economic Impact of Korlym The primary source of revenue for Corcept emanates from the sales of Korlym. The drug has showcased remarkable growth, evidenced by a 39.1% year-over-year sales increase, culminating in $310.6 million during the first half of 2024. This growth is attributed to robust demand and an unprecedented number of patients being prescribed the medication. ◉ Corcept's Stock Growth Factors ● Potential of Relacorilant: Positive GRACE study results suggest relacorilant could be a valuable treatment for Cushing's syndrome, potentially driving revenue growth. ● Pipeline Diversification: Corcept's ongoing exploration of relacorilant in GRADIENT study demonstrates commitment to expanding pipeline. ● Regulatory Progress: Successful completion of GRACE study positions Corcept for a new drug application in late 2024. ● Market Need: Successful relacorilant could fill significant unmet medical need for Cushing's syndrome. Investent Advice by Naranj Capital Buy Corcept Therapeutics NASDAQ:CORT ● Buy Range- 38 - 40 ● Target- 55 - 58 ● Potential Return- 35% - 40% ● Invest Duration- 12-14 Months ◉ Market Capitalization - $4.42 B ◉ Peer Companies ● Prestige Consumer Healthcare NYSE:PBH - $3.644 B ● Jazz Pharmaceuticals NASDAQ:JAZZ - $6.766 B ● Amphastar Pharmaceuticals NASDAQ:AMPH - $2.423 B ● Organon NYSE:OGN - $5.142 B ◉ Relative Strength ➖ The chart distinctly demonstrates that NASDAQ:CORT has significantly surpassed the US Smallcap 2000 index, attaining an impressive annual return of 30%, marking a remarkable accomplishment. ◉ Technical Aspects ● Monthly Chart ➖ The historical chart shows that the stock price is trending upward, marked by a sequence of higher highs and higher lows. ➖ Having recently moved out of the parallel channel, the price is set for additional gains. ● Daily Chart ➖ After an extended period of consolidation, the stock price has formed an Inverted Head & Shoulders pattern. ➖ Post-breakout, the stock has stabilized above the breakout point and is now striving for new highs. ➖ A surge in trading volume suggests that buyers are currently showing significant interest. ◉ Revenue & Profit Analysis ● Year-on-year ➖ In the fiscal year 2023, revenue experienced a significant increase of 20.4%, amounting to $482.4 million, compared to $401.9 million in fiscal year 2022. ➖ However, EBITDA faced a downturn, decreasing to $108.3 million in FY23 from $113.9 million in FY22. ➖ The EBITDA margin also saw a reduction, falling to 22.46% from 28.34% in FY22. ➖ Moreover, diluted earnings per share (EPS) rose by 8% year-over-year, climbing to $0.94 in FY23, up from $0.87 in FY22. **While the growth in EBITDA might raise some concerns, it's crucial to acknowledge that the company is heavily investing in its research and development sector, and this investment has seen substantial increases over the years. ● Quarter-on-quarter ➖ In the most recent June quarter, the company reached an impressive achievement, with quarterly sales hitting a record high of $163.8 million. This represents a 12% increase from the $146.8 million reported in the March quarter and a substantial 39% growth compared to $117.7 million in the corresponding quarter of the previous year. ➖ Additionally, EBITDA rose from $29.6 million to $36.2 million during the latest quarter. ◉ Valuation ◉ PE Ratio ● PE vs Median PE ➖ Corcept Therapeutics sustained a median price-to-earnings ratio of 19.7x from December 2019 to 2023. ➖ Presently, with a price-to-earnings ratio of 35.3x, the stock seems to be relatively expensive. ● PE vs. Peers PE ➖ CORT's Price-To-Earnings Ratio stands at 35.3x, making it quite pricey when compared to the average of its peers, which is only 13.6x. ● PE vs. Industry PE ➖ CORT's valuation seems high, as it has a Price-To-Earnings Ratio of 35.3x, which is considerably above the US Pharmaceuticals industry average of 19x. ◉ PB Ratio ● PB vs. Peers PB ➖ The current price-to-book (P/B) ratio suggests that the stock is slightly undervalued, sitting at 7.4x compared to the peer average of 10.8x. ➖ However, it's important to note that a P/B ratio of 7.4x is typically seen as significantly overvalued. ● PB vs. Industry PB ➖ When we analyze the P/B ratio against the industry standard, CORT stands out as being notably overvalued, with its P/B ratio of 7.4x far exceeding the industry average of just 1.7x. ● PEG Ratio ➖ The stock currently seems to present a compelling investment opportunity, featuring a PEG ratio of 0.84. ◉ Cash Flow Analysis ➖ In FY23, operating cash flow increased to $127 million, compared to $120.3 million in FY22. However, it's essential to recognize that when examining the overall trend from FY19 to FY23, there has been a decline in cash flow from operations. ◉ Debt Analysis ➖ CORT operates without any debt, showcasing the robust financial health of the company. ◉ Top Shareholders ➖ Blackrock presently possesses a significant 15.8% ownership in this stock, while The Vanguard Group maintains approximately 9.1% stakes. ◉ Conclusion Following a comprehensive examination of technical and fundamental metrics, our assessment indicates that Corcept Therapeutics possesses substantial growth potential within the US biotechnology sector. Notwithstanding elevated valuations, the company's increasing research and development expenditures demonstrate a strong commitment to its future prospects. Consequently, we consider Corcept Therapeutics a prudent investment choice at this juncture.
NASDAQ:CORTLong
by NaranjCapital
Antitrust Threat Looms Over Google, Shares Could Plummet by 10%!Google's dominance might be ending. A U.S. judge has decided that the company's control over search is unfair competition. This could lead to Alphabet, Google's parent company, being split up and a major change in online advertising. A new era of search could be coming, as the internet's main player may soon lose its power. Technical Analysis The share price has surged by over 190% since hitting its lowest point during the Covid-19 crash. Following a previous peak of $152, the stock experienced a significant drop and subsequently entered a prolonged phase of consolidation. After approximately 2.5 years of this price stabilization, the stock finally broke through its prior resistance in April 2024. This significant breakthrough resulted in an impressive surge, propelled the price to a new all-time high of $193. However, the stock price faced considerable resistance at that level, resulted in a decline and eventually breaking down of its upward-trending parallel channel. The stock is likely to experience a sharp decline of about 10%, finding support somewhere between $132 and $131.
NASDAQ:GOOGShort
by NaranjCapital
NOC vs LMT: A Valuation War Between Top Defence Manufacturers!ABOUT COMPANIES Northrop Grumman NYSE:NOC excels in advanced aircraft systems, divided into four main areas: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. Aeronautics Systems designs and manufactures cutting-edge aircraft for the U.S. military and global clients. Defense Systems integrates battle management and weaponry, while Mission Systems delivers innovative solutions for defense and intelligence. Space Systems focuses on solutions for national security and commercial purposes. Established in 1939 by John K. Northrop and others, the company is headquartered in Falls Church, VA. Lockheed Martin NYSE:LMT stands as a top global security and aerospace company, dedicated to the research, design, and production of advanced technology systems. It operates in four primary segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment focuses on military aircraft, including combat and drones. MFC specializes in air and missile defense and precision strike systems. RMS develops military and commercial helicopters and cyber solutions, while the Space segment creates satellites and defense systems. Founded in 1912, the company is located in Bethesda, MD. MARKET CAPITALIZATION ● Northrop Grumman (NYSE: NOC) - $75.96 Billion ● Lockheed Martin (NYSE: LMT) - $135.53 Billion TECHNICAL ASPECTS ● Northrop Grumman ➖ The monthly chart shows that the stock price is currently on a distinct upward path. ➖ Previously, it faced resistance around the $360 level, caused a notable pullback. ➖ Subsequently, the price formed a Double Bottom pattern and broke out successfully. ➖ This breakout drove the price to an all-time high near the $556 level but the price started declining from there. ➖ Nevertheless, the stock price found strong support around the $420 level, allowed it to bounce back. ➖ Currently, the stock is approaching its previous all-time high, and if it can overcome that resistance, we can anticipate further price increases in the coming days. ● Lockheed Martin ➖ This stock is on a strong upward trajectory, consistently achieving higher highs and higher lows. ➖ Following a significant breakout around the $500 mark, the stock price surged and is now trading at $568.5, just shy of its all-time peak of $578.7. ➖ From a technical perspective, the price is hovering just below the upper boundary of a parallel channel, which may act as a resistance point. ➖ However, if the price can break through this range and maintain that momentum, we could see even greater upward movement ahead. Relative Strength ● The chart shows that the NYSE Composite TVC:NYA has provided a solid return on investment of about 18% in the last year. In comparison, Northrop Grumman and Lockheed Martin have done even better, with returns of around 20% and 27%, respectively. REVENUE BREAKDOWN ● Northrop Grumman The company derives its income from four main segments. ➖ The largest share comes from the space systems segment, contributing around 33%, which equates to $14.34 billion out of a total revenue of $43 billion. ➖ Next, the aeronautics systems segment adds nearly 27%, bringing in $11.61 billion of the overall revenue. ➖ The mission systems segment follows closely, accounting for about 26%, or $11.12 billion of the total. ➖ Finally, the defense systems segment generates nearly 14%, totaling $5.99 billion of the overall revenue. ● Lockheed Martin Similar to Northrop Grumman, this company also operates through four segments to drive its revenue. ➖ The aeronautics segment leads the way, contributing around 38.4%, which amounts to nearly $28.77 billion of the total revenue of $74.85 billion. ➖ The rotary and mission systems segment accounts for 26.4% of revenue, equating to $19.76 billion. ➖ Next, the space segment contributes 17.8%, which is $13.33 billion. ➖ Finally, the missile and fire control segment makes up 17.4%, totaling $12.99 billion of the overall revenue. REVENUE & PROFIT ANALYSIS ● Northrop Grumman Revenue ➖ For the FY23 the revenue has jumped by 7.3% to $39.3 B from $36.6 B in FY22. ➖ In the recent June quarter there is no significant surge in revenue as the recent quarterly revenue stands at $10.2 B compared to $10.1 B in the march 2024. But from the last year June quarter the revenue has grown by almost 6% from $9.6 B. Profit ➖ The operating profit has experienced a decline, with FY23 reporting only $2.9 billion, a drop from $6.3 billion in FY22. ➖ In the latest June quarter, the operating profit held steady at $1.3 billion, unchanged from the March quarter. Basic EPS (LTM) ➖ The basic EPS saw a slight rise in June, climbing to $15.26 (LTM) from $14.33 (LTM) in March 2024. However, compared to the same quarter last year, there has been a significant drop from $30.23 (LTM) Analyzing these numbers shows that although revenue has risen, the company is having difficulty producing profits, which may impact the share price in the near term. ● Lockheed Martin Revenue ➖ In FY23, the company experienced a slight revenue increase of 2.4%, rising to $67.6 billion from $66 billion in FY22. ➖ During the recent June quarter, revenue reached $18.1 billion, up from $17.2 billion in the March quarter. Compared to the same quarter last year, this represents a significant growth of approximately 8.6%, up from $16.7 billion. Profit ➖ The operating income has experienced a year-over-year increase. For FY23, it reached $9.0 billion, marking a 23% rise from $7.3 billion in FY22. ➖ However, there hasn't been a notable change in operating profit on a quarter-over-quarter basis. In June, the operating profit stood at $2.2 billion, slightly up from $2.1 billion in March. This figure is consistent with the operating profit reported in the same quarter last year. Basic EPS (LTM) ➖ The basic EPS stood at $27.58 (LTM) in June 2024 ➖ Over the past year, there has been no notable growth in EPS (LTM) Lockheed Martin demonstrates a more robust financial standing compared to Northman Grumman. VALUATION ● P/E Ratio ➖ P/E vs. Median P/E (1) Northrop Grumman's current price-to-earnings ratio over the past twelve months stands at 33.2x, which appears elevated when compared to its four-year median of 15.2x. (2) Lockheed Martin's recent twelve-month p/e ratio is 20.1x, also showing a rise relative to its four-year median of 16.2x. ➖ P/E vs. Industry P/E (1) NOC shows a fair valuation with a Price-To-Earnings Ratio of 33.2x, which is just below the US Aerospace & Defense Industry average of 33.3x. (2) On the other hand, LMT, with a P/E of 20.1x, seems to be undervalued relative to the industry average of 33.3x. ● P/B Ratio ➖ NOC's current P/B ratio of 5.3x appears inflated when stacked against the US Aerospace & Defense Industry average of 3.2x. ➖ In the case of LMT, it stands out as significantly overvalued, boasting a P/B ratio of 21.9x, which is far above the industry average of 3.2x. FREE CASH FLOW ANALYSIS ● Northrop Grumman ➖ In FY23, cash flow from operations saw a remarkable increase, climbing to $3.9 billion, a notable rise from $2.9 billion in FY22. ➖ In the most recent quarter, this figure reached $4.4 billion, up from $3.9 billion in March. ● Lockheed Martin ➖ There was little change in operating cash flow, with FY23 reporting $7.9 billion, which is nearly the same as the $7.8 billion recorded in FY22. ➖ On a quarterly basis, there has been an uptick; for the June quarter, operating cash flow stood at $8.8 billion, an increase from $8.0 billion in March and $7.7 billion in the same quarter last year. DEBT ANALYSIS ● NOC currently has a debt of $16.3 billion, resulting in a debt-to-equity ratio of 114%. While this may raise some concerns, the company boasts an interest coverage ratio of 5.2, indicating a solid ability to manage interest payments on its debt. ● In contrast, LMT carries a debt of $19.3 billion, leading to a debt-to-equity ratio of 311%, which suggests poor financial health. However, with an impressive interest coverage ratio of 8.9, the company is in a strong position to meet its interest obligations. TOP SHAREHOLDERS ● Northrop Grumman ➖ State Street Global has a notable 9.59% ownership in this firm, while The Vanguard Group possesses a considerable 8.22% stake. ● Lockheed Martin ➖ In addition to the 11.2% held by Lockheed Martin's Employee Stock Ownership Plan (ESOP), State Street Global and The Vanguard Group own 15.1% and 8.99% respectively. ➖ BlackRock also maintains a significant 7.13% interest in this company. CONCLUSION After reviewing all the financial metrics, it becomes evident that each company possesses distinct strengths and weaknesses. It's difficult to determine which one is the superior investment choice at this moment. A look at the monthly chart indicates that both companies are currently at a high point, but they could be good candidates for accumulation during any significant downturns. In 2023, the US spent $916 billion on defense, which was more than any other country. This was an increase of $55 billion from 2022. and this figure could increase given the current global landscape. Therefore, companies like Northrop Grumman and Lockheed Martin are expected to perform well in the foreseeable future.
NYSE:NOCLong
by NaranjCapital
Concerned about aging? Start investing in Addus now!The aging U.S. population is set to double by 2050, increasing the need for caregivers. Addus HomeCare Corporation, based in Frisco, Texas, provides essential personal care, hospice, and home health services. With a market cap of $2.35 billion, Addus reported $1.115 billion in revenue in June 2024, with a 27% profit increase. The company is debt-free and has major shareholders like Blackrock and The Vanguard Group. EPS is forecasted to grow significantly by December 2025. With a growing need for home healthcare services, the company is well-positioned to expand its customer base and market presence. Company Overview Addus HomeCare Corporation and its subsidiaries offer personal care services for the elderly, disabled, and those at risk of hospitalization in the U.S. It operates in three areas: Personal Care, Hospice, and Home Health. The Personal Care segment helps with daily activities like bathing, grooming, and meal preparation. The Hospice segment provides care and support for terminally ill patients and their families. The Home Health segment delivers skilled nursing and therapy services for those recovering from illness or hospitalization. Its clients include government agencies, managed care organizations, insurers, and private individuals. Founded in 1979, Addus is based in Frisco, Texas. Investment Advice by Naranj Capital Buy Addus Homecare Corporation NASDAQ:ADUS ● Buy Range- 120 - 125 ● Target- 150 - 160 ● Potential Return- 25-30% ● Duration- 10 -12 Months Market Capitalization - $ 2.35B Sector - Healthcare (Nursing) Technical Analysis ● The monthly chart indicates a clear upward trend in prices. ● Earlier, the stock peaked near the 129 (128.8 to be precise) level before experiencing a correction, which was subsequently followed by an elongated consolidation period from November 2020 to July 2024. ● Recently, the stock has successfully made a multi-year breakout of the previous resistance zone and has maintained its position above this breakout level. ● We expect this momentum to persist, leading to further price increases in the days ahead. Entry, Exit & Stop-loss ● Entry with Capital allocation strategy (1) consider adding 50% of your desired quantity at the current market price (132 - 133). (2) The second buying opportunity will be in the 120 - 122 range, where you can also add rest 50% of your quantity. ● Target Chart analysis indicates a promising upside potential of 25-30% for this stock from the best buying level, with a target around the 155 to 160. There is also a strong likelihood that the stock could exceed this target. ● Stoploss It is crucial to implement a strict stop-loss below the 115 level, as we anticipate that the stock may encounter challenges if it drops to this point. Revenue Breakdown The company generates its revenue through three primary segments. (1) The personal care sector represents around 74.2% of the overall revenue, totaling $827 million out of $1.11 billion. (2) Meanwhile, hospice services contribute nearly 19.7%, amounting to $219.8 million of the total revenue. (3) The home health segment accounts for approximately 6.1%, which translates to $67.8 million of the overall revenue. Sales & Profit Analysis ● A noticeable rise in revenue has been observed. For the June quarter, revenue reached $1.115 billion, marking an 11.6% increase from $999 million in June 2023 (YoY) and a 2.5% rise from $1.08 billion in March 2024 (QoQ). ● Additionally, profits surged by 27% in the latest quarter, climbing to $68.89 million from $53.83 million in the same quarter last year, and up 5% from $65.67 million in March 2024. ● The profit margin has also improved, increasing from 5.4% to 6.2% year-on-year. ● The basic EPS for the June 2024 quarter is reported at 4.28, marking a significant increase of 27% from 3.37 in the same quarter last year. Peer Companies (1) Privia Health Group (NASDAQ: PRVA) - $ 2.41B NASDAQ:PRVA (2) Amedisys (NASDAQ: AMED) - $ 3.21B NASDAQ:AMED (3) Astrana Health (NASDAQ: ASTH) - $ 2.33B NASDAQ:ASTH Valuation ● P/E vs Fair P/E Ratio ➖ The current PE ratio stands at 34.1x, slightly expensive to the estimated Fair PE of 28.7x. ● P/E Ratio vs Peers ➖ ADUS offers great value with a Price-To-Earnings Ratio of 34.1x, significantly lower than the peer average of 62.7x. ● P/E Ratio vs Industry P/E ➖ ADUS seems to come at a higher price, boasting a Price-To-Earnings Ratio of 34.1x, notably surpassing the US Healthcare industry average of 26.2x. Debt Analysis ➖ ADUS stands proudly as a debt-free entity, a remarkable transformation from five years ago when its debt to equity ratio stood at 12.9%. This significant shift underscores the company's commitment to financial health and stability. Top Shareholders ● Blackrock currently holds a substantial 16% stake in this stock, reflecting an impressive increase of 11.2% since the March quarter. ● Meanwhile, The Vanguard Group has also boosted its investment, raising its stake by 8.5% from the previous quarter, bringing their total holding to 7.74%. Earnings per Share Growth Forecasts Experts forecast that the earnings per share (EPS) could increase from $4.28 to $4.51 by December 2024, and further rise to $5.03 by December 2025. Conclusion With the growing need for home healthcare services, the company is well-positioned to broaden its customer base and enhance its market presence.
NASDAQ:ADUSLong
by NaranjCapital
1